BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 10363988)

  • 21. Construction and characterization of bispecific costimulatory molecules containing a minimized CD86 (B7-2) domain and single-chain antibody fragments for tumor targeting.
    Rohrbach F; Gerstmayer B; Biburger M; Wels W
    Clin Cancer Res; 2000 Nov; 6(11):4314-22. PubMed ID: 11106249
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antitumor immunity elicited by tumor cells transfected with B7-2, a second ligand for CD28/CTLA-4 costimulatory molecules.
    Yang G; Hellström KE; Hellström I; Chen L
    J Immunol; 1995 Mar; 154(6):2794-800. PubMed ID: 7533183
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Host B7-1 and B7-2 costimulatory molecules contribute to the eradication of B7-1-transfected P815 tumor cells via a CD8+ T cell-dependent mechanism.
    La Motte RN; Sharpe AH; Bluestone JA; Mokyr MB
    J Immunol; 1999 Apr; 162(8):4817-23. PubMed ID: 10202025
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumor rejection requires a CTLA4 ligand provided by the host or expressed on the tumor: superiority of B7-1 over B7-2 for active tumor immunization.
    Gajewski TF; Fallarino F; Uyttenhove C; Boon T
    J Immunol; 1996 Apr; 156(8):2909-17. PubMed ID: 8609411
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combination B7-Fc fusion protein treatment and Treg cell depletion therapy.
    Liu A; Hu P; Khawli LA; Epstein AL
    Clin Cancer Res; 2005 Dec; 11(23):8492-502. PubMed ID: 16322313
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Admixture of a recombinant vaccinia virus containing the gene for the costimulatory molecule B7 and a recombinant vaccinia virus containing a tumor-associated antigen gene results in enhanced specific T-cell responses and antitumor immunity.
    Hodge JW; McLaughlin JP; Abrams SI; Shupert WL; Schlom J; Kantor JA
    Cancer Res; 1995 Aug; 55(16):3598-603. PubMed ID: 7543017
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Protein transfer of glycosyl-phosphatidylinositol-B7-1 into tumor cell membranes: a novel approach to tumor immunotherapy.
    McHugh RS; Nagarajan S; Wang YC; Sell KW; Selvaraj P
    Cancer Res; 1999 May; 59(10):2433-7. PubMed ID: 10344754
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A novel approach to cancer immunotherapy: tumor cells decorated with CD80 generate effective antitumor immunity.
    Singh NP; Yolcu ES; Taylor DD; Gercel-Taylor C; Metzinger DS; Dreisbach SK; Shirwan H
    Cancer Res; 2003 Jul; 63(14):4067-73. PubMed ID: 12874008
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The capacity of the natural ligands for CD28 to drive IL-4 expression in naïve and antigen-primed CD4+ and CD8+ T cells.
    Bian Y; Hiraoka S; Tomura M; Zhou XY; Yashiro-Ohtani Y; Mori Y; Shimizu J; Ono S; Dunussi-Joannopoulos K; Wolf S; Fujiwara H
    Int Immunol; 2005 Jan; 17(1):73-83. PubMed ID: 15569772
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Potent activity of soluble B7-IgG fusion proteins in therapy of established tumors and as vaccine adjuvant.
    Sturmhoefel K; Lee K; Gray GS; Thomas J; Zollner R; O'Toole M; Swiniarski H; Dorner A; Wolf SF
    Cancer Res; 1999 Oct; 59(19):4964-72. PubMed ID: 10519410
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The expression of CD70 and CD80 by gene-modified tumor cells induces an antitumor response depending on the MHC status.
    Douin-Echinard V; Bornes S; Rochaix P; Tilkin AF; Peron JM; Bonnet J; Favre G; Couderc B
    Cancer Gene Ther; 2000 Dec; 7(12):1543-56. PubMed ID: 11228533
    [TBL] [Abstract][Full Text] [Related]  

  • 32. B7-1 (CD80)-gene transfer combined with interleukin-12 administration elicits protective and therapeutic immunity against mouse hepatocellular carcinoma.
    Tatsumi T; Takehara T; Kanto T; Kuzushita N; Ito A; Kasahara A; Sasaki Y; Hori M; Hayashi N
    Hepatology; 1999 Aug; 30(2):422-9. PubMed ID: 10421650
    [TBL] [Abstract][Full Text] [Related]  

  • 33. B7-1 expression decreases tumorigenicity and induces partial systemic immunity to murine neuroblastoma deficient in major histocompatibility complex and costimulatory molecules.
    Katsanis E; Xu Z; Bausero MA; Dancisak BB; Gorden KB; Davis G; Gray GS; Orchard PJ; Blazar BR
    Cancer Gene Ther; 1995 Mar; 2(1):39-46. PubMed ID: 7542553
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors.
    Reilly RT; Machiels JP; Emens LA; Ercolini AM; Okoye FI; Lei RY; Weintraub D; Jaffee EM
    Cancer Res; 2001 Feb; 61(3):880-3. PubMed ID: 11221874
    [TBL] [Abstract][Full Text] [Related]  

  • 35. B7.2-Ig fusion proteins enhance IL-4-dependent differentiation of tumor-sensitized CD8+ cytotoxic T lymphocyte precursors.
    Hiraoka S; Takeuchi N; Bian Y; Nakahara H; Kogo M; Dunussi-Joannopoulos K; Wolf S; Ono S; Fujiwara H
    Int Immunol; 2005 Aug; 17(8):1071-9. PubMed ID: 16027141
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vaccine therapy of established tumors in the absence of autoimmunity.
    Hodge JW; Grosenbach DW; Aarts WM; Poole DJ; Schlom J
    Clin Cancer Res; 2003 May; 9(5):1837-49. PubMed ID: 12738742
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Blockade of costimulatory molecules B7-1 (CD80) and B7-2 (CD86) down-regulates induction of contact sensitivity by haptenated epidermal cells.
    Katayama I; Matsunaga T; Yokozeki H; Nishioka K
    Br J Dermatol; 1997 Jun; 136(6):846-52. PubMed ID: 9217815
    [TBL] [Abstract][Full Text] [Related]  

  • 38. B7 costimulatory molecules from malignant cells in patients with b-cell chronic lymphoproliferative disorders trigger t-cell proliferation.
    Trentin L; Perin A; Siviero M; Piazza F; Facco M; Gurrieri C; Galvan S; Adami F; Agostini C; Pizzolo G; Zambello R; Semenzato G
    Cancer; 2000 Sep; 89(6):1259-68. PubMed ID: 11002221
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Specificity and longevity of antitumor immune responses induced by B7-transfected tumors.
    Townsend SE; Su FW; Atherton JM; Allison JP
    Cancer Res; 1994 Dec; 54(24):6477-83. PubMed ID: 7527298
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intramuscular gene transfer of soluble B7.1/IgG(1) fusion cDNA induces potent antitumor immunity as an adjuvant for DNA vaccination.
    Zhou ZF; Peretz Y; Chang Y; Miao DS; Li X; Prud'homme GJ
    Cancer Gene Ther; 2003 Jun; 10(6):491-9. PubMed ID: 12768195
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.